Deborah Toppmeyer

Clinical trials

• Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

  Principal investigator · Terminated · Phase 1, Phase 2

  Rutgers, The State University of New Jersey

  2009–2015
• Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

  Principal investigator · Completed · Phase 2

  Rutgers, The State University of New Jersey

  2008–2015
• Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

  Principal investigator · Terminated · Phase 2

  Rutgers, The State University of New Jersey

  2007–2017
• Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

  Principal investigator · Terminated · Phase 2

  Rutgers, The State University of New Jersey

  2006–2016